Humanigen

$15.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-3.55%) Today

+$0.09 (+0.59%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Humanigen and other stocks, options, and ETFs commission-free!

About HGEN

Humanigen, Inc. Common Stock, also called Humanigen, is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA. The listed name for HGEN is Humanigen, Inc. Common Stock.

CEO

Cameron Durrant

Employees

Headquarters

Burlingame, California

Founded

2000

Market Cap

820.93M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

875.08K

High Today

$17.21

Low Today

$13.97

Open Price

$17.10

Volume

1.15M

52 Week High

$33.95

52 Week Low

$1.75

Analyst Ratings

86%

of 7 ratings

Buy

86%

Hold

14%

Sell

HGEN Earnings

-$0.16

-$0.11

-$0.05

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 15, Pre-Market